Patisiran
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 23/100
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin-mediated Amyloidosis With Cardiomyopathy
Conditions
Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy
Trial Timeline
— → —
NCT ID
NCT05505838About Patisiran
Patisiran is a pre-clinical stage product being developed by Alnylam Pharmaceuticals for Transthyretin-mediated Amyloidosis With Cardiomyopathy. The current trial status is completed. This product is registered under clinical trial identifier NCT05505838. Target conditions include Transthyretin-mediated Amyloidosis With Cardiomyopathy, ATTR Amyloidosis With Cardiomyopathy.
What happened to similar drugs?
0 of 5 similar drugs in Transthyretin-mediated Amyloidosis With Cardiomyopathy were approved
Approved (0) Terminated (0) Active (5)
Hype Score Breakdown
Clinical
3
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05505838 | Pre-clinical | Completed |
| NCT05023889 | Phase 1 | Active |
| NCT04201418 | Pre-clinical | Completed |
| NCT03862807 | Phase 3 | Completed |
| NCT02510261 | Phase 3 | Completed |
| NCT01617967 | Phase 2 | Completed |
Competing Products
9 competing products in Transthyretin-mediated Amyloidosis With Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 29 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| Patisiran | Alnylam Pharmaceuticals | Pre-clinical | 23 |
| ALN-TTRSC02 + Sterile Normal Saline (0.9% NaCl) | Alnylam Pharmaceuticals | Phase 1 | 26 |
| Nucresiran + Vutrisiran | Alnylam Pharmaceuticals | Phase 3 | 44 |
| ALN-TTRSC04 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 26 |
| Eplontersen | Ionis Pharmaceuticals | Phase 3 | 41 |
| Inotersen + Eplontersen | Ionis Pharmaceuticals | Phase 3 | 37 |